Oudard Stéphane, Quoix Elisabeth, Jenabian Arash, Bergougnoux Loïc, Chouahnia Kader, Ferrero Jean-Marc, Misset Jean-Louis, Spaëth Dominique
Hôpital Européen Georges Pompidou, Paris, France.
Therapie. 2009 Jan-Feb;64(1):17-25. doi: 10.2515/therapie/2009002. Epub 2009 May 26.
The aim of the study was to assess the efficacy and safety of epoetin beta once-weekly in anemic patients with solid tumors treated with chemotherapy.
Prospective, open-label, multicenter, single-arm study of epoetin beta 30 000 I.U. once-weekly in anemic patients with solid tumors receiving chemotherapy (n = 365).
Epoetin beta increased mean haemoglobin (Hb) levels from 10.3 +/- 0.9 g/dL at baseline to 12.3+/-2.0 g/dL at week 12. The response rate was achieved in 61% (CI 95%: 55-68) of the patients. The mean Hb level increased was 1.8 g/dL (CI 95%: 1.5-2,0); in lung cancer patients (n = 102) Hb increase was 2.7 g/dL. Treatment with epoetin beta was well tolerated; only 1.4 % patients had thrombotic events.
Epoetin beta (30 000 I.U. once weekly) increased Hb levels and was well-tolerated to correct anemia in patients with solid tumors treated with chemotherapy.
本研究旨在评估每周一次使用β-促红细胞生成素对接受化疗的实体瘤贫血患者的疗效和安全性。
对365例接受化疗的实体瘤贫血患者进行前瞻性、开放标签、多中心、单臂研究，每周一次使用30000国际单位的β-促红细胞生成素。
β-促红细胞生成素使平均血红蛋白（Hb）水平从基线时的10.3±0.9g/dL升至第12周时的12.3±2.0g/dL。61%（95%置信区间：55-68）的患者达到缓解率。平均Hb水平升高1.8g/dL（95%置信区间：1.5-2.0）；肺癌患者（n=102）的Hb升高2.7g/dL。β-促红细胞生成素治疗耐受性良好；仅有1.4%的患者发生血栓事件。
β-促红细胞生成素（每周一次30000国际单位）可提高Hb水平，且耐受性良好，可纠正接受化疗的实体瘤患者的贫血。
